Want to join the conversation?
Drugmaker $VRTX reported a narrower 1Q16 loss driven by product revenue from cystic fibrosis treating drugs Orkambi and Kalydeco. Net loss narrowed to $41.63MM or $0.17 per share from $198.61MM or $0.83 per share last year. Revenue grew to $398.08MM from $138.51MM. Non-GAAP EPS was $0.09 compared to loss of $0.62 per share a year ago.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?